News

Pharmabiz9d
US FDA accepts for review Milestone Pharma’s response to CRL for Cardamyst nasal spray
US FDA accepts for review Milestone Pharma’s response to CRL for Cardamyst nasal spray: Montreal Monday, July 14, 2025, 11:00 Hrs [IST] Milestone Pharmaceuticals Inc., a biophar ...
TMCnet12d
Milestone Pharmaceuticals Announces FDA Acceptance of the Company's Response to the CRL for CARDAMYST™ (etripamil) Nasal Spray
Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) (Milestone) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review Milestone’s response to issues raised in the ...
PharmiWeb12d
Ultomiris Drug Market 2025 - 2034
Reports DescriptionAccording to the analysis conducted by Custom Market Insights (CMI), the Ultomiris drug market is ...
Paroxysmal Nocturnal Hemoglobinuria Treatment Market Set For Robust Growth Through 2034, Driven By Advancing Clinical Development Pipeline Delveinsight
The Paroxysmal Nocturnal Hemoglobinuria treatment market is experiencing significant expansion, driven by increasing disease awareness, rising preval ...
The Bakersfield Californian15d
Market Barriers Continue to Challenge PNH Treatment Optimization Despite Emerging Options,
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, chronic blood disorder that can affect individuals of any age, race, or gender, though it ...
Yahoo Finance15d
Market Barriers Continue to Challenge PNH Treatment Optimization ...
Hematologists are actively adapting their prescribing strategies in paroxysmal nocturnal hemoglobinuria (PNH), with future pipeline entrants poised to further reshape the treatment landscape.
Morningstar15d
Market Barriers Continue to Challenge PNH Treatment Optimization ...
Market Barriers Continue to Challenge PNH Treatment Optimization Despite Emerging Options, According to Spherix Global Insights Provided by GlobeNewswire Jul 8, 2025, 11:22:35 AM ...